Company Profile
Hangzhou Valgen Medtech Co., Ltd. (brand name: Dejin Medical) is a China-based manufacturer of transcatheter structural heart valve repair systems, headquartered in Hangzhou, Zhejiang. Founded in August 2015 and incubated by DeNO Medical Group, the privately held company is recognized as a unicorn enterprise in China's medical device sector. It employs over 280 people and maintains an innovation R＆D center in Shenzhen, serving cardiac centers and hospitals across China and expanding into global markets.
Core Products ＆ Technologies
Transcatheter Mitral Valve Repair
• DragonFly™ Transcatheter Mitral Valve Clip System: China's first domestically developed transcatheter mitral valve edge-to-edge repair (TEER) device via transfemoral venous approach; NMPA approved November 2023, CE MDR certified April 2025; features 45-degree free-angle locking, central sealing net, unilateral independent grasping, and full graduation dial system
• MitralStitch® Mitral Valve Repair System: Transapical device enabling both edge-to-edge repair and artificial chordal implantation; entered first-in-human clinical study in 2018
Transcatheter Tricuspid Valve Repair
• DragonFly-T™ Transcatheter Tricuspid Valve Clip System: China's first transfemoral tricuspid valve repair device; FIM study 12-month follow-up data disclosed April 2026, demonstrating stability and feasibility
Accessories ＆ Complementary Devices
• DragonPath™ Atrial Septal Puncture System: Transfemoral venous transseptal puncture system for left heart access
• Magpie™ Valvuloplasty Balloon Dilatation Catheter: Cardiac aortic valve balloon dilatation catheter
• Adjustable Curved Guide Sheath: NMPA Class III approved April 2026, optimizing TEER procedural delivery
• Firework™ Stiff Guidewires: Interventional guidewires for cardiovascular procedures
Market Position ＆ Certifications
Valgen Medtech holds a leading position in China's transcatheter valve repair market, competing with Huanqing Medical, Xinrui Medical, and Akcome Medical. Key strengths include:
• 10+ years of structural heart innovation heritage
• Market leadership: DragonFly™ achieved 47.14% market share in China's TEER segment in 2025 with 2,043 implants
• Regulatory compliance: NMPA approved, CE MDR certified, and registered in Hong Kong (China), Indonesia, Colombia, Turkey, Peru, Vietnam, and other markets
• Intellectual property: Over 600 patent applications filed globally with more than 200 granted
• National program participation: Led the national 14th Five-Year Key R＆D Program for transcatheter mitral valve clip system development
Corporate Timeline
2015 — Founded in Hangzhou by DeNO Medical Group
2018 — MitralStitch® completed first-in-human clinical study
2020 — DragonFly™ completed first-in-human clinical trial led by Academician Wang Jian'an
2021 — Secured Series B financing; DragonFly™ entered NMPA Innovation Device Special Review Program
2022 — Led the national 14th Five-Year Key R＆D Program
2023 — DragonFly™ received NMPA approval, becoming the first domestic TEER device in China
2025 — DragonFly™ obtained CE MDR certification; achieved 47.14% domestic TEER market share with 2,043 implants; global cumulative implants exceeded 3,000 cases; approved in Brazil, Saudi Arabia, Turkey, Peru, Colombia, Indonesia, Vietnam, and other markets; pre-tax profit turned positive
2026 — Vietnam first implant completed; adjustable curved guide sheath received NMPA approval; recognized as Zhejiang Unicorn Enterprise; DragonFly-T FIM 12-month data presented at CHINA VALVE; Broncus Medical acquired approximately 4.9% stake
Target Markets ＆ Applications
• Degenerative Mitral Regurgitation (DMR): Transcatheter edge-to-edge repair for patients with posterior leaflet prolapse or flail
• Functional Mitral Regurgitation (FMR): TEER treatment for ischemic and non-ischemic cardiomyopathy patients
• Tricuspid Regurgitation (TR): Minimally invasive tricuspid valve repair via transfemoral approach
• High-Risk Surgical Patients: Minimally invasive alternatives for patients unsuitable for open-heart surgery
Contact Information
Global Headquarters
Address: 1F 101-108, Building C, No. 58 Qiuyi Road, Changhe Street, Binjiang District, Hangzhou, Zhejiang, China
Email: fengwanyun@valgenmed.com
Website: www.valgenmed.com
R＆D Center
Address: 6F, Aotexun Power Building, No. 3 Songpingshan Road, Xili Street, Nanshan District, Shenzhen, Guangdong, China
